Mayo Clinic Infectious Diseases Board Review

While infections have always played an important role in the history of mankind, advances in science and technology as well as rapid globalization have resulted in an unprecedented wave of new and old infections thrust into the limelight. The recent pandemic of H1N1 influenza virus infection demonstrates the recurrent theme of emerging and reemerging pathogens that continue to impact public health and patient care areas. Drug resistance among various organisms (not limited to bacteria) has unfortunately become the expectation and, not infrequently, we have been left with few or no efficacious treatment options, an experience not witnessed in more than 7 decades. Human immunodeficiency virus infection continues to challenge our abilities to provide the desired level of care in most areas of the world. Novel syndromes of infection continue to be defined as newer forms of immunosuppression and the development of unique medical devices become standard practice in all areas of medicine and surgery. For trainees and practitioners in the field of infectious diseases today, these factors mandate intense study to establish an expertise in the field that is required to provide best practices now and beyond. This board review will be pivotal in that education. This book is designed and intended primarily for infectious diseases trainees and practitioners preparing for the infectious disease subspecialty examination of the American Board of Internal Medicine. We believe that this book will also be useful to infectious diseases practitioners as well as general internists and other clinicians who desire a comprehensive but practical overview of contemporary infectious diseases topics.

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 793
Author(s):  
Ying Huang ◽  
Monique S. França ◽  
James D. Allen ◽  
Hua Shi ◽  
Ted M. Ross

Vaccination is the best way to prevent influenza virus infections, but the diversity of antigenically distinct isolates is a persistent challenge for vaccine development. In order to conquer the antigenic variability and improve influenza virus vaccine efficacy, our research group has developed computationally optimized broadly reactive antigens (COBRAs) in the form of recombinant hemagglutinins (rHAs) to elicit broader immune responses. However, previous COBRA H1N1 vaccines do not elicit immune responses that neutralize H1N1 virus strains in circulation during the recent years. In order to update our COBRA vaccine, two new candidate COBRA HA vaccines, Y2 and Y4, were generated using a new seasonal-based COBRA methodology derived from H1N1 isolates that circulated during 2013–2019. In this study, the effectiveness of COBRA Y2 and Y4 vaccines were evaluated in mice, and the elicited immune responses were compared to those generated by historical H1 COBRA HA and wild-type H1N1 HA vaccines. Mice vaccinated with the next generation COBRA HA vaccines effectively protected against morbidity and mortality after infection with H1N1 influenza viruses. The antibodies elicited by the COBRA HA vaccines were highly cross-reactive with influenza A (H1N1) pdm09-like viruses isolated from 2009 to 2021, especially with the most recent circulating viruses from 2019 to 2021. Furthermore, viral loads in lungs of mice vaccinated with Y2 and Y4 were dramatically reduced to low or undetectable levels, resulting in minimal lung injury compared to wild-type HA vaccines following H1N1 influenza virus infection.


RSC Advances ◽  
2017 ◽  
Vol 7 (56) ◽  
pp. 35290-35296 ◽  
Author(s):  
Zhengfang Lin ◽  
Yinghua Li ◽  
Min Guo ◽  
Misi Xiao ◽  
Changbing Wang ◽  
...  

Zanamivir is an effective drug for influenza virus infection, but strong molecular polarity and aqueous solubility limit its clinical application.


2020 ◽  
Vol 7 (5) ◽  
pp. 804
Author(s):  
Rakesh K. Yadav ◽  
Raj K. ◽  
Kachnar V. ◽  
Manoj K. Mathur ◽  
Amitabh D. Shukla

Background: Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been considered very specific for rheumatoid arthritis (RA). Some studies have shown that these antibodies can be positive in infectious diseases like tuberculosis, human immunodeficiency virus infection, etc.Methods: Eighty patients of tuberculosis both pulmonary and extra-pulmonary tuberculosis and thirty patients of human immunodeficiency virus were enrolled in this study from inpatient and outpatient departments from September 2018 to August 2019. Anti-CCP antibody test was done in all the patient by enzyme linked immunosorbent assay.Results: Fifty-three patients were of pulmonary tuberculosis, 27 patients were extra-pulmonary tuberculosis and 30 patients were human immunodeficiency virus infection. Of the 53 cases of pulmonary tuberculosis, 21 (39.6%) cases were positive for anti-CCP antibodies and 32 (60.4%) cases were negative for the same. Of the 27 cases of extra-pulmonary tuberculosis, 3(11.1%) cases were positive for anti-CCP antibodies and 24 (88.9%) cases were negative. Of the 53 patients of pulmonary tuberculosis, 16 were sputum positive and 37 were sputum negative. Of those withsputum positive 9 (56.2%) cases were positive for anti-CCP antibodies and those with sputum negative, 12 (32.4%) cases were positive for anti-CCP antibodies. Of the 30 cases of human immunodeficiency virus, 5 (16.7%) cases were positive for anti-CCP antibodies and 25 (83.3%) cases were negative.Conclusions: Anti-CCP can be positive in cases of infectious diseases like tuberculosis and human immunodeficiency virus. Positivity of anti-CCP antibodies for tuberculosis is more for pulmonary (more for sputum-positive than sputum-negative) than extra-pulmonary tuberculosis. Anti-CCP, thus is not very specific for rheumatoid arthritis.


2010 ◽  
Vol 106 (10) ◽  
pp. 1517-1519 ◽  
Author(s):  
Nikolaos Akritidis ◽  
Maria Mastora ◽  
Gerasimos Baxevanos ◽  
Georgios Dimos ◽  
Georgios Pappas

1995 ◽  
Vol 85 (7) ◽  
pp. 362-374 ◽  
Author(s):  
O Memar ◽  
R Cirelli ◽  
P Lee ◽  
SK Tyring

Infection with the human immunodeficiency virus (HIV) leads to a chronic disarmament of the immune system. The process is progressive, having different manifestations as the status of the immune system slowly deteriorates. Some of the most common manifestations of HIV infection are cutaneous in origin, and they can have infectious, neoplastic, or noninfectious or non-neoplastic etiologies. A brief history of HIV is given, and the most common cutaneous presentations of the virus infection of interest to podiatrists are outlined.


Sign in / Sign up

Export Citation Format

Share Document